Brokers Offer Predictions for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at B. Riley issued their FY2024 earnings per share estimates for Nektar Therapeutics in a research note issued to investors on Tuesday, January 7th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings per share of ($0.83) for the year. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.71) per share. B. Riley also issued estimates for Nektar Therapeutics' Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.65) EPS.

A number of other research firms have also recently weighed in on NKTR. Piper Sandler initiated coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an "overweight" rating and a $7.00 price target for the company. HC Wainwright started coverage on shares of Nektar Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $6.50 price target on the stock. Finally, BTIG Research reissued a "buy" rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Nektar Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $4.08.

Nektar Therapeutics Trading Down 9.6 %

Shares of NKTR traded down $0.11 during midday trading on Friday, reaching $1.03. 1,650,697 shares of the company were exchanged, compared to its average volume of 2,063,483. Nektar Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.93. The stock has a 50-day moving average price of $1.09 and a 200-day moving average price of $1.21. The company has a market cap of $189.99 million, a price-to-earnings ratio of -1.23 and a beta of 0.59.

Insider Activity at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $1.01, for a total transaction of $47,464.95. Following the sale, the chief executive officer now directly owns 1,195,710 shares in the company, valued at approximately $1,207,667.10. This represents a 3.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the sale, the insider now directly owns 351,892 shares in the company, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock valued at $149,878 over the last ninety days. Corporate insiders own 3.71% of the company's stock.

Institutional Investors Weigh In On Nektar Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Samlyn Capital LLC bought a new position in shares of Nektar Therapeutics during the second quarter worth about $11,728,000. Eventide Asset Management LLC increased its position in Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company's stock valued at $12,220,000 after acquiring an additional 1,870,904 shares during the period. Millennium Management LLC raised its stake in Nektar Therapeutics by 56.1% during the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company's stock valued at $5,778,000 after acquiring an additional 1,674,924 shares in the last quarter. Nantahala Capital Management LLC raised its stake in Nektar Therapeutics by 66.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company's stock valued at $5,096,000 after acquiring an additional 1,634,046 shares in the last quarter. Finally, Armistice Capital LLC acquired a new position in Nektar Therapeutics during the 2nd quarter worth $1,037,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.